[
  {
    "title": "In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation",
    "source": "FierceBiotech",
    "published": "Nov 21, 2025 4:16pm",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "fda",
        "FDA",
        "US"
      ],
      "concepts": [
        "biotech",
        "volatility"
      ],
      "methods": []
    },
    "clusters": [
      "Regulatory / Biotech Business",
      "Regulatory / Biotech Business",
      "Other",
      "Other",
      "Regulatory / Biotech Business"
    ]
  },
  {
    "title": " FDA says it's hiring more than 1,000 new staffers, launches new comms program for review process",
    "source": "FierceBiotech",
    "published": "Nov 21, 2025 11:20am",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "fda",
        "FDA"
      ],
      "concepts": [
        "review process"
      ],
      "methods": []
    },
    "clusters": [
      "Regulatory / Biotech Business",
      "Regulatory / Biotech Business",
      "Regulatory / Biotech Business"
    ]
  },
  {
    "title": "Chutes & Ladders—Gilead abruptly parts ways with general counsel",
    "source": "FierceBiotech",
    "published": "Nov 20, 2025 4:26pm",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "gilead"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Major Biotech Companies"
    ]
  },
  {
    "title": "Fierce Biotech Layoff Tracker 2025: Applied Tx lays off 46% of staff; Ensoma makes cuts",
    "source": "FierceBiotech",
    "published": "Dec 23, 2024 11:52am",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [
        "biotech"
      ],
      "methods": []
    },
    "clusters": [
      "Other"
    ]
  },
  {
    "title": "Nurix trims workforce as pivotal trial for lead BTK degrader kicks off",
    "source": "FierceBiotech",
    "published": "Nov 20, 2025 8:42pm",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "BTK"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Other"
    ]
  },
  {
    "title": "Contineum's J&J-partnered MS drug fails to improve vision in phase 2",
    "source": "FierceBiotech",
    "published": "Nov 20, 2025 5:05pm",
    "topics": {
      "scientific_terms": [
        "phase"
      ],
      "companies": [
        "MS"
      ],
      "concepts": [
        "AI-biotech"
      ],
      "methods": []
    },
    "clusters": [
      "Other",
      "Other",
      "AI in Biotech"
    ]
  },
  {
    "title": "Moderna's reshaping rolls on with 3 more pipeline purges",
    "source": "FierceBiotech",
    "published": "Nov 20, 2025 3:36pm",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "moderna"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Major Biotech Companies"
    ]
  },
  {
    "title": "How a 'healthy exchange of ideas' with RFK Jr. kick-started FDA's gene therapy push",
    "source": "FierceBiotech",
    "published": "Nov 18, 2025 4:37am",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "RFK",
        "fda",
        "FDA"
      ],
      "concepts": [],
      "methods": [
        "gene therapy"
      ]
    },
    "clusters": [
      "Other",
      "Regulatory / Biotech Business",
      "Regulatory / Biotech Business",
      "Other"
    ]
  },
  {
    "title": "Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3",
    "source": "FierceBiotech",
    "published": "Nov 20, 2025 11:02am",
    "topics": {
      "scientific_terms": [
        "phase"
      ],
      "companies": [
        "pfizer"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Other",
      "Major Biotech Companies"
    ]
  },
  {
    "title": "Ensoma halves workforce after transitioning genetic medicine to the clinic",
    "source": "FierceBiotech",
    "published": "Nov 20, 2025 9:55am",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "Applied Tx lays off 46% of workforce as rare disease drug approval looks out of reach",
    "source": "FierceBiotech",
    "published": "Nov 20, 2025 8:39am",
    "topics": {
      "scientific_terms": [
        "disease"
      ],
      "companies": [],
      "concepts": [
        "approval"
      ],
      "methods": []
    },
    "clusters": [
      "Other",
      "Other"
    ]
  },
  {
    "title": "Aspen enriches Parkinson's cell therapy trial with Kite-backed $115M series C",
    "source": "FierceBiotech",
    "published": "Nov 19, 2025 5:04pm",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "GSK picks Flagship's Quotient, ProFound as 1st biotech partners for $7B pact",
    "source": "FierceBiotech",
    "published": "Nov 19, 2025 3:35pm",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "GSK"
      ],
      "concepts": [
        "biotech"
      ],
      "methods": []
    },
    "clusters": [
      "Other",
      "Other"
    ]
  },
  {
    "title": "Merck KGaA links up with Flagship's Valo Health in search for Parkinson's targets, offers $3B in biobucks",
    "source": "FierceBiotech",
    "published": "Nov 19, 2025 2:19pm",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "Fierce Biotech Fundraising Tracker '25: Aspen adds $115M; Solve Tx secures $120M",
    "source": "FierceBiotech",
    "published": "Dec 23, 2024 12:22pm",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [
        "biotech",
        "AI-biotech"
      ],
      "methods": []
    },
    "clusters": [
      "Other",
      "AI in Biotech"
    ]
  },
  {
    "title": "Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases'",
    "source": "FierceBiotech",
    "published": "Nov 20, 2025 4:38am",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "novartis",
        "CEO"
      ],
      "concepts": [
        "AI-biotech"
      ],
      "methods": []
    },
    "clusters": [
      "Major Biotech Companies",
      "Other",
      "AI in Biotech"
    ]
  },
  {
    "title": "Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO",
    "source": "FierceBiotech",
    "published": "Nov 19, 2025 11:43am",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "CAR",
        "CEO"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Other",
      "Other"
    ]
  },
  {
    "title": "Celltrion still thinking bigger than biosimilars with option for $350M antibody deal",
    "source": "FierceBiotech",
    "published": "Nov 19, 2025 9:14am",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir",
    "source": "FierceBiotech",
    "published": "Nov 19, 2025 8:14am",
    "topics": {
      "scientific_terms": [
        "phase"
      ],
      "companies": [
        "gilead",
        "HIV"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Other",
      "Major Biotech Companies",
      "Other"
    ]
  },
  {
    "title": "'Gilead wants us to rebuild': Why Galapagos isn't allowed to go extinct after turbulent year",
    "source": "FierceBiotech",
    "published": "Nov 19, 2025 6:56am",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "gilead"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Major Biotech Companies"
    ]
  },
  {
    "title": "'At the top of our game': Lilly picks Philadelphia as next spot for early-stage biotech lab space",
    "source": "FierceBiotech",
    "published": "Nov 18, 2025 4:47pm",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [
        "biotech"
      ],
      "methods": []
    },
    "clusters": [
      "Other"
    ]
  },
  {
    "title": "GSK pens $50M LTZ pact to join Big Pharma peers in emerging myeloid cell engager space",
    "source": "FierceBiotech",
    "published": "Nov 19, 2025 4:41am",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "GSK",
        "LTZ"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Other",
      "Other"
    ]
  },
  {
    "title": "'We're built for it': Why Cytokinetics doesn't want Big Pharma support to help it supersede Camzyos",
    "source": "FierceBiotech",
    "published": "Nov 17, 2025 9:43am",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "How Biogen is returning to its roots with a West Coast immunology outpost",
    "source": "FierceBiotech",
    "published": "Nov 18, 2025 10:46am",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "biogen"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Major Biotech Companies"
    ]
  },
  {
    "title": "Vanda tackles Wegovy-driven vomiting, sparking race to phase 3",
    "source": "FierceBiotech",
    "published": "Nov 18, 2025 10:19am",
    "topics": {
      "scientific_terms": [
        "phase"
      ],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Other"
    ]
  },
  {
    "title": "Six key obesity deals in 2025",
    "source": "Labiotech.eu",
    "published": "Fri, 21 Nov 2025 14:00:00 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes",
    "source": "Labiotech.eu",
    "published": "Fri, 21 Nov 2025 09:00:00 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "BIO",
        "DISCO"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Other",
      "Other"
    ]
  },
  {
    "title": "Eight CAR-T cell therapy companies you should know about",
    "source": "Labiotech.eu",
    "published": "Wed, 19 Nov 2025 14:00:00 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "CAR"
      ],
      "concepts": [],
      "methods": []
    },
    "clusters": [
      "Other"
    ]
  },
  {
    "title": "Twice the punch: The emergence of dual-payload antibody and peptide drug conjugates",
    "source": "Labiotech.eu",
    "published": "Tue, 18 Nov 2025 14:03:30 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "On the fast track to the clinic: early decisions in drug development",
    "source": "Labiotech.eu",
    "published": "Tue, 18 Nov 2025 09:00:00 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "Precision psychiatry is the future of mental healthcare",
    "source": "Labiotech.eu",
    "published": "Mon, 17 Nov 2025 14:00:00 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "10 gene therapy companies you should know about",
    "source": "Labiotech.eu",
    "published": "Fri, 14 Nov 2025 14:10:17 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": [
        "gene therapy"
      ]
    },
    "clusters": [
      "Other"
    ]
  },
  {
    "title": "Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology",
    "source": "Labiotech.eu",
    "published": "Fri, 14 Nov 2025 09:00:00 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [
        "BIO"
      ],
      "concepts": [
        "biotech"
      ],
      "methods": []
    },
    "clusters": [
      "Other",
      "Other"
    ]
  },
  {
    "title": "iGEM Jamboree: leap into the synthetic biology future",
    "source": "Labiotech.eu",
    "published": "Thu, 13 Nov 2025 14:00:00 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "Biosimilars: a vital remedy for Europe’s healthcare challenges",
    "source": "Labiotech.eu",
    "published": "Thu, 13 Nov 2025 08:30:00 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  },
  {
    "title": "Swiss biotech going strong in 2025: 19 companies to put on your radar",
    "source": "Labiotech.eu",
    "published": "Wed, 12 Nov 2025 14:10:08 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [
        "biotech"
      ],
      "methods": []
    },
    "clusters": [
      "Other"
    ]
  },
  {
    "title": "New cancer cell discovery sheds light on childhood blood cancer",
    "source": "Labiotech.eu",
    "published": "Wed, 12 Nov 2025 10:00:00 +0000",
    "topics": {
      "scientific_terms": [],
      "companies": [],
      "concepts": [],
      "methods": []
    },
    "clusters": []
  }
]